Albiglutide

What is Albiglutide?

Albiglutide is a once-weekly long-acting GLP-1 receptor agonist developed by Human Genome Sciences and GlaxoSmithKline as a recombinant fusion protein consisting of two tandem copies of a DPP-4-resistant GLP-1(7-36) variant (with an Ala8→Gly substitution to resist N-terminal DPP-4 cleavage) genetically fused to human serum albumin. The albumin-fusion strategy extends plasma half-life to approximately 5 days through albumin's natural FcRn-mediated recycling pathway, enabling once-weekly subcutaneous dosing. Albiglutide was approved by the FDA in April 2014 as Tanzeum and by the EMA in March 2014 as Eperzan, both for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic drugs and basal insulin. The HARMONY phase 3 program tested albiglutide across multiple type 2 diabetes settings (HARMONY 1-8) and the cardiovascular outcomes trial HARMONY OUTCOMES (published in Lancet 2018, PMID 30291013) demonstrated that albiglutide reduced major adverse cardiovascular events (MACE) by 22 percent versus placebo in patients with type 2 diabetes and established cardiovascular disease over a median 1.6 years — a positive CV outcomes signal that joined liraglutide (LEADER), semaglutide (SUSTAIN-6), and dulaglutide (REWIND) in establishing the GLP-1 receptor agonist class CV benefit. Despite the positive CV signal, GlaxoSmithKline announced in July 2017 that it would discontinue manufacturing and sale of albiglutide globally, citing weak commercial performance against the dominant once-weekly competitors semaglutide (Novo Nordisk's Ozempic launched late 2017) and dulaglutide (Eli Lilly's Trulicity launched 2014). Manufacturing ceased in late 2017 and existing supply was depleted through 2018. Albiglutide is no longer commercially available in any major market — making it the principal example of an FDA-approved GLP-1 receptor agonist with a positive cardiovascular outcomes trial that was withdrawn for commercial rather than safety reasons. The molecule remains historically and pharmacologically interesting as a successful demonstration of albumin-fusion long-acting peptide design and as a benchmark in the GLP-1 receptor agonist class.

What Albiglutide Is Investigated For

Albiglutide is a historical and pharmacology-reference topic, not a currently available drug. It was an FDA- and EMA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes from April 2014 until its global commercial withdrawal by GlaxoSmithKline in late 2017-2018. Three things make it worth knowing about. First, the design: albiglutide demonstrated that albumin-fusion can deliver a clinically successful once-weekly peptide therapeutic, with half-life around 5 days extended through albumin's FcRn-mediated recycling pathway. The albumin fusion concept has remained an active strategy for other peptide drugs although second-generation approaches (lipidation in semaglutide and tirzepatide; PEGylation in some pegylated peptides) have proven more commercially successful. Second, the cardiovascular outcomes signal: the HARMONY OUTCOMES trial (Lancet 2018) demonstrated that albiglutide reduced major adverse cardiovascular events by 22 percent versus placebo over a median 1.6 years in patients with type 2 diabetes and established cardiovascular disease — joining liraglutide (LEADER), semaglutide (SUSTAIN-6), and dulaglutide (REWIND) in establishing the GLP-1 receptor agonist class CV benefit, and providing the methodologically cleanest positive CV signal among the GLP-1 trials. Third, the commercial story: despite the positive CV outcomes signal and FDA/EMA approval, GSK chose to discontinue albiglutide globally because it could not compete on efficacy or commercial performance against dulaglutide (Trulicity, Eli Lilly) and especially the about-to-launch semaglutide (Ozempic, Novo Nordisk). Albiglutide produced ~0.6-0.9 percent HbA1c reduction and ~0.6-0.8 kg weight loss in HARMONY trials — figures that were competitive in 2014 but were dwarfed by semaglutide's HbA1c reductions and substantially larger weight loss within a few years. The honest framing is that albiglutide is a textbook example of a clinically validated drug withdrawn because the competitive landscape moved past it — a cautionary tale about pharmaceutical economics, not safety.

History & Discovery

Albiglutide originated at Human Genome Sciences (HGS) in Rockville, Maryland in the early 2000s as part of HGS's albumin-fusion peptide platform. The albumin-fusion strategy — genetically fusing peptide therapeutics to human serum albumin to extend plasma half-life through albumin's natural FcRn-mediated recycling pathway — was a major focus of HGS's biopharmaceutical pipeline. Albiglutide was designed as two tandem copies of a DPP-4-resistant GLP-1(7-36) variant fused to the N-terminus of human serum albumin, producing a 645-amino-acid recombinant fusion protein. Preclinical and early clinical development through the late 2000s established the once-weekly pharmacokinetic profile and GLP-1 receptor agonism. GlaxoSmithKline acquired Human Genome Sciences in August 2012 for $3 billion (cash plus assumption of debt), bringing the albiglutide program in-house alongside other HGS assets including the lupus drug belimumab (Benlysta). The HARMONY phase 3 program ran from 2009 to 2014 across multiple type 2 diabetes treatment settings. HARMONY 1 tested albiglutide in combination with pioglitazone and metformin; HARMONY 2 was monotherapy; HARMONY 3 tested combination with metformin; HARMONY 4 was head-to-head versus insulin glargine; HARMONY 5 was combination with metformin and glimepiride versus pioglitazone (PMID 25406730); HARMONY 6 was combination with insulin lispro versus continued lispro alone; HARMONY 7 was head-to-head versus liraglutide (PMID 24703047); HARMONY 8 was monotherapy in renal impairment. The integrated efficacy and safety analyses (Ahrén 2017, PMID 28284167; Home 2017, PMID 28683300) characterized the program output: ~0.6-0.9 percent HbA1c reduction, ~0.6-0.8 kg weight loss, generally favorable tolerability with relatively few GI side effects but more injection-site reactions than other GLP-1 receptor agonists. Albiglutide was approved by the FDA on April 15, 2014 as Tanzeum and by the EMA on March 21, 2014 as Eperzan, both for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic drugs and basal insulin. The class boxed warning for medullary thyroid carcinoma and MEN-2 (originating from rodent C-cell tumor signals seen across the GLP-1 receptor agonist class) applied. Initial commercial uptake was modest. The competitive landscape in 2014 already included exenatide (Byetta, Bydureon), liraglutide (Victoza), and dulaglutide (Trulicity, launched September 2014) — and over the following years continued to evolve with the launch of semaglutide (Ozempic, December 2017) and tirzepatide (Mounjaro, May 2022). GlaxoSmithKline announced on July 26, 2017 that it would discontinue manufacturing and global sales of albiglutide, citing weak commercial performance. GSK explicitly stated that the withdrawal was a commercial decision, not a safety decision, and that no new safety signal had prompted the action. Manufacturing ceased in late 2017, and existing supply was depleted through 2018 via wholesalers. Patients on albiglutide were transitioned to other GLP-1 receptor agonists (most commonly dulaglutide or semaglutide). The HARMONY OUTCOMES cardiovascular outcomes trial (Hernandez 2018, PMID 30291013), which had been designed and run during the era of albiglutide's commercial availability, was published in October 2018 in Lancet — a year after the discontinuation announcement. The trial demonstrated a 22 percent reduction in MACE versus placebo over median 1.6 years, contributing to the establishment of the GLP-1 class CV benefit alongside LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide). The CV signal was clinically meaningful but came too late to alter the commercial decision. Albiglutide thus stands as the principal example of an FDA-approved GLP-1 receptor agonist with a positive cardiovascular outcomes signal that was withdrawn for commercial rather than safety reasons — a cautionary tale about pharmaceutical economics and competitive dynamics in a fast-moving therapeutic class.

How It Works

Albiglutide is a once-weekly diabetes drug that was on the market from 2014 to 2018. It works the same way as Ozempic and Trulicity — it activates the GLP-1 receptor, which makes you produce more insulin after meals, makes you feel full sooner, and slows your stomach down. It was made by sticking GLP-1 onto albumin (a big protein in your blood that lasts a long time), which is what gave it the once-weekly half-life. The drug worked, but not as well as semaglutide (Ozempic), so GSK pulled it from the market in 2017. The HARMONY OUTCOMES trial later showed it reduced heart attacks and strokes by 22 percent — but by then GSK had already decided to discontinue it.

Albiglutide is a recombinant fusion protein produced in Saccharomyces cerevisiae yeast, consisting of two tandem copies of a modified human GLP-1(7-36) sequence (with an Ala8→Gly substitution that confers DPP-4 resistance — DPP-4 is the principal degrading enzyme of native GLP-1, which has a half-life of only ~2 minutes) genetically fused to the N-terminus of human serum albumin (HSA). The total molecule is 645 amino acids. The albumin moiety extends plasma half-life to approximately 5 days (compared with native GLP-1's ~2 minute half-life and exenatide's ~2.5 hour half-life) through two mechanisms: HSA's intrinsically long half-life (~19 days, mediated by binding to the neonatal Fc receptor FcRn on vascular endothelial cells, which recycles HSA back to circulation rather than allowing it to be degraded by lysosomal pathways) and HSA's large size (~67 kDa as fusion vs ~3.3 kDa for unfused GLP-1) which limits renal clearance. Albiglutide signals through the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, hypothalamic appetite circuits, gastrointestinal smooth muscle, cardiomyocytes, vascular endothelium, and other tissues. GLP-1R activation drives multiple cAMP-mediated downstream effects: glucose-dependent insulin secretion (the safety-defining feature of the GLP-1 class — insulin release is enhanced only when glucose is elevated, minimizing hypoglycemia risk), glucagon suppression in pancreatic alpha cells, slowed gastric emptying (which contributes to postprandial glucose lowering and to the early satiety perception underlying weight loss), central appetite suppression through hypothalamic and brainstem effects, and various cardiovascular and inflammatory effects that may underlie the class CV benefit. The pharmacokinetic profile of albiglutide is meaningfully different from other long-acting GLP-1 receptor agonists. Albumin-fused albiglutide produces relatively flat steady-state plasma concentrations after repeated weekly dosing, with limited peak-trough variation. Lipidation-based long-acting agonists (liraglutide with C16 fatty-acid attachment for daily dosing; semaglutide with C18 fatty-acid attachment plus additional spacer modifications for weekly dosing) achieve their long half-lives through reversible albumin binding rather than covalent fusion, producing more dynamic pharmacokinetic profiles that may better engage GLP-1R signaling pathways relevant to weight loss and HbA1c reduction. The exenatide once-weekly formulation (Bydureon) uses a microsphere depot strategy to achieve weekly dosing. Dulaglutide is an Fc-fusion of two modified GLP-1 sequences with an IgG4 Fc fragment, producing a similar pharmacokinetic profile to albiglutide but with somewhat better efficacy. The HARMONY phase 3 program (HARMONY 1-8) tested albiglutide in monotherapy, in combination with metformin, sulfonylureas, pioglitazone, basal insulin, and other regimens, and in head-to-head comparison with sitagliptin, glimepiride, pioglitazone, and liraglutide (HARMONY 7, PMID 24703047). Across the program, albiglutide produced ~0.6-0.9 percent HbA1c reduction and ~0.6-0.8 kg weight loss versus placebo. In HARMONY 7 (head-to-head vs liraglutide 1.8 mg daily), albiglutide met non-inferiority criteria but produced numerically smaller HbA1c reduction (-0.78 vs -0.99 percent at 32 weeks) — a result that contributed to the perception that albiglutide was on the lower end of the GLP-1 class efficacy spectrum. HARMONY OUTCOMES (PMID 30291013) was the cardiovascular outcomes trial, randomizing 9,463 patients with type 2 diabetes and established cardiovascular disease to albiglutide 30-50 mg once-weekly subcutaneously versus placebo on top of standard care. The primary endpoint of MACE (CV death, non-fatal MI, non-fatal stroke) occurred in 7 percent of albiglutide patients vs 9 percent of placebo over median 1.6 years (HR 0.78, 95% CI 0.68-0.90, P<0.001 for superiority) — a 22 percent relative risk reduction. The trial joined LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) in establishing the GLP-1 class CV benefit, and was widely regarded as one of the methodologically cleaner trials in that set. The CV outcomes were published in October 2018, by which time GSK had already announced (July 2017) and effectively executed (manufacturing ceased late 2017) the global commercial withdrawal of albiglutide.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Albiglutide:

• 01Why albiglutide produced numerically smaller HbA1c reduction and weight loss than other long-acting GLP-1 receptor agonists (especially semaglutide) despite the same molecular target — likely involving the steady-state pharmacokinetic profile of albumin fusion versus the more dynamic lipidation-based pharmacokinetics, but not definitively characterized.
• 02Whether the albumin-fusion strategy will be revisited in next-generation peptide drug design with improved efficacy, or whether lipidation has definitively superseded it.
• 03What the long-term real-world outcomes of albiglutide therapy would have been if commercial availability had continued for a decade — a counterfactual that cannot be answered.
• 04Whether the cardiovascular benefit observed in HARMONY OUTCOMES was a class effect (consistent with LEADER, SUSTAIN-6, REWIND) or had molecule-specific contributions that would have required longer follow-up to characterize.
• 05How the albiglutide discontinuation lessons apply to current and future drug-development decisions in fast-moving therapeutic classes — albiglutide is cited in pharmaceutical economics literature as a case study in commercial obsolescence of clinically valid drugs.

Forms & Administration

Albiglutide was administered as a once-weekly subcutaneous injection at doses of 30 mg or 50 mg, supplied as a single-dose lyophilized pen (Tanzeum/Eperzan) requiring reconstitution before injection. Injection sites included the abdomen, thigh, and upper arm with site rotation. The starting dose was 30 mg once weekly with optional escalation to 50 mg once weekly if glycemic targets were not achieved. Administration could be on any day of the week, with at least 4 days between doses if a dose was missed. Albiglutide is no longer commercially available — manufacturing ceased in late 2017 and existing supply was depleted through 2018. No biosimilar or generic alternative exists. Patients previously on albiglutide were transitioned to other GLP-1 receptor agonists during the discontinuation period.

Common Questions

Who Albiglutide Is NOT For

Drug & Supplement Interactions

Albiglutide's drug-interaction profile during its commercial period was the standard GLP-1 receptor agonist class profile. Concurrent use with insulin, sulfonylureas, or meglitinides increased hypoglycemia risk and required downward titration of those agents at albiglutide initiation. Slowed gastric emptying (a class effect) altered absorption rate of orally administered medications, with potential clinical relevance for narrow-therapeutic-index agents (warfarin, levothyroxine, oral contraceptives, antiepileptics, oral antibiotics) — though for albiglutide specifically the gastric-emptying effect was relatively modest compared with shorter-acting agents like exenatide. Concurrent use with other GLP-1 receptor agonists, DPP-4 inhibitors, or other agents with overlapping mechanism was not recommended. As albiglutide is no longer available, these interaction concerns are now historical.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions